Existing BC risk prediction models provided similar risk discrimination across multiple cohorts, although there was overestimation of risk for high-risk individuals, which supports development of a unified risk model for diverse populations that leverages appropriate incidence rates.
Abstract
Background: Several breast cancer (BC) risk prediction models have been developed to provide personal risk assessments. Though individually validated, their performance has not been systematically evaluated across a wide range of populations or ages. Methods: We harmonized individual-level baseline questionnaire data and incident BC diagnoses from 21 cohorts from North America, Europe, and Australia participating in the Breast Cancer Risk Prediction Project. Five-year absolute risk of invasive BC was estimated for five established risk prediction models using classical risk factors only. Discrimination was evaluated by area under the curve (AUC). Calibration was assessed using average and risk-decile specific expected to observed (E/O) ratios. Performance metrics were meta-analyzed across cohorts and models. Metaregression tested associations between cohort characteristics and performance metrics. Results: This analysis included 1,595,977 women aged 20-75 years, enrolled in studies between 1976-2015, with 19,062 (1.2%) invasive BC cases ascertained within 5 years from exposure assessment. Age-adjusted AUCs were similar across models and cohorts (pooled AUCs by model: 0.57-0.58), while E/O ratios varied substantially (pooled E/O ratios by model: 0.83-1.25). Overestimation was common among predicted high-risk individuals (>3%). No appreciable differences in model performance by cohort age, birth year, race, and variable missingness emerged. Calibration improved after assigning race-specific incidence rates. Conclusion: Existing BC risk prediction models provided similar risk discrimination across multiple cohorts, although there was overestimation of risk for high-risk individuals. Performance variation across cohorts was not driven by specific characteristics, which supports development of a unified risk model for diverse populations that leverages appropriate incidence rates.
BCa and inherited genetic susceptibility jointly contribute to increased risk of multiple common diseases, supporting the integration of genetic risk stratification into survivorship care.
Annabelle Ashworth, Zhu-Qing Shi, Huy Tran et al.· JNCI Cancer Spectrum· 0 citations
Background & Objective: Breast cancer in women aged ≤40 years is biologically aggressive and carries a disproportionate cancer-specific mortality risk. Existing prognostic tools predominantly predict overall survival, rarely account for competing risks of non-cancer death, and have not evaluated whether primary treatme...
Umema Tariq, Yousaf Ali, Mohammad Idrees et al.· Journal of Saidu Medical Col...· 0 citations
The nomogram model incorporating clinicopathological and demographic variables showed higher predictive accuracy than conventional TNM staging for CSS in CRC patients and indicated that the nomogram provided higher net benefit for prognostic risk classification than the traditional TNM staging system across a wide rang...
Yi Liu, Xiao-Jun Tang, Zhi Liu et al.· Cancer Investigation· 0 citations
Background & AimsWe previously developed multiple machine-learning and regression-based risk prediction models using retrospective electronic health records (EHR) to estimate near-term risk of pancreatic cancer (PC). This pilot study aimed to assess the feasibility of an early detection strategy combining initial EHR-b...
Bechien U. Wu, T. Luong, Eva Lustigova et al.· medRxiv· 0 citations
Summary Prostate cancer progression varies across patients. Understanding disease trajectories and mortality risk is important for improved healthcare. This study developed a time-inhomogeneous Markov model using territory-wide electronic medical records from Hong Kong to estimate 10-year disease progression. The model...
Jia-Qi Wang, Yuan-Shi Jiao, D. Craig et al.· iScience· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.